Terje R Pedersen

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi request reprint High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
    Terje R Pedersen
    Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    JAMA 294:2437-45. 2005
  2. ncbi request reprint Lipid-lowering drugs and risk for cancer
    Terje R Pedersen
    Center for Preventive Medicine, Oslo University Hospital, Oslo, Norway
    Curr Atheroscler Rep 11:350-7. 2009
  3. doi request reprint Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
    Terje R Pedersen
    Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
    Am J Cardiol 106:354-9. 2010
  4. doi request reprint Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering
    Terje R Pedersen
    Centre for Preventative Medicine, Ulleval University Hospital, University of Oslo, Oslo, Norway
    Am J Cardiovasc Drugs 10:10-7. 2010
  5. doi request reprint Intensive lipid-lowering therapy for patients with aortic stenosis
    Terje R Pedersen
    Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    Am J Cardiol 102:1571-6. 2008
  6. doi request reprint Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study
    Ingar Holme
    Center of Preventive Medicine, Oslo University Hospital, Sector Ullevål, Oslo, Norway
    Eur J Cardiovasc Prev Rehabil 16:315-20. 2009
  7. ncbi request reprint Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)
    Ingar Holme
    Center of Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    Ann Med 40:456-64. 2008
  8. doi request reprint Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)
    Ingar Holme
    Centre of Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    Atherosclerosis 205:522-7. 2009
  9. doi request reprint Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial
    Ingar Holme
    Centre of Preventive Medicine, Oslo University Hospital, Ulleval, Oslo, Norway
    Am J Cardiol 105:1802-8. 2010
  10. ncbi request reprint Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
    Terje R Pedersen
    Center for Preventive Medicine, Ulleval University Hospital, N 0407 Oslo, Norway
    Am J Cardiol 94:720-4. 2004

Detail Information

Publications35

  1. ncbi request reprint High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
    Terje R Pedersen
    Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    JAMA 294:2437-45. 2005
    ..Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease...
  2. ncbi request reprint Lipid-lowering drugs and risk for cancer
    Terje R Pedersen
    Center for Preventive Medicine, Oslo University Hospital, Oslo, Norway
    Curr Atheroscler Rep 11:350-7. 2009
    ..Whether statins and other lipid-lowering drugs will increase the risk of cancer when used over several decades is at present unknown...
  3. doi request reprint Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
    Terje R Pedersen
    Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
    Am J Cardiol 106:354-9. 2010
    ..The 2 treatment regimens were well tolerated. In conclusion, our analysis provides support for the strategy of placing patients with recent MI on intensive statin therapy and maintaining the high dose over the long term, beyond 2 years...
  4. doi request reprint Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering
    Terje R Pedersen
    Centre for Preventative Medicine, Ulleval University Hospital, University of Oslo, Oslo, Norway
    Am J Cardiovasc Drugs 10:10-7. 2010
    ..Future cholesterol-lowering modalities must be able to demonstrate efficacy and good tolerability in large-scale clinical trials...
  5. doi request reprint Intensive lipid-lowering therapy for patients with aortic stenosis
    Terje R Pedersen
    Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    Am J Cardiol 102:1571-6. 2008
    ..In conclusion, the SEAS and ASTRONOMER studies will help resolve the contradictory findings of SALTIRE and RAAVE on the benefit of intensive lipid-lowering treatment in aortic stenosis...
  6. doi request reprint Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study
    Ingar Holme
    Center of Preventive Medicine, Oslo University Hospital, Sector Ullevål, Oslo, Norway
    Eur J Cardiovasc Prev Rehabil 16:315-20. 2009
    ..78-1.01) using atorvastatin 80 mg versus simvastatin 20-40 mg in patients with coronary heart disease (P=0.07). Adherence was high in both treatment groups but significantly higher in patients treated with simvastatin...
  7. ncbi request reprint Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)
    Ingar Holme
    Center of Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    Ann Med 40:456-64. 2008
    ..Few studies have looked into the ability of measurements of apolipoprotein B (apoB) and apolipoprotein A-1 (apoA-1) or apoB/apoA-1 to predict new coronary heart disease (CHD) events in patients with CHD on statin treatment...
  8. doi request reprint Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)
    Ingar Holme
    Centre of Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    Atherosclerosis 205:522-7. 2009
    ..Very few, if any, studies have assessed the ability of apolipoproteins to predict new-onset of congestive heart failure (HF) in statin-treated patients with coronary heart disease (CHD)...
  9. doi request reprint Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial
    Ingar Holme
    Centre of Preventive Medicine, Oslo University Hospital, Ulleval, Oslo, Norway
    Am J Cardiol 105:1802-8. 2010
    ....
  10. ncbi request reprint Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
    Terje R Pedersen
    Center for Preventive Medicine, Ulleval University Hospital, N 0407 Oslo, Norway
    Am J Cardiol 94:720-4. 2004
    ..2 +/- 0.3 mmol/L (46 mg/dl). Drug treatment before randomization consisted of statins in 77% of patients, aspirin in 78.9%, beta blockers in 75.1%, and angiotensin-converting enzyme inhibitors in 30%...
  11. ncbi request reprint Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease
    Torgun Waehre
    Research Institute of Internal Medicine, Department of Cardiology, Rikshospitalet University Hospital, Oslo, Norway
    J Am Coll Cardiol 41:1460-7. 2003
    ..We sought to investigate whether the activation of the chemokine network observed in patients with coronary artery disease (CAD) could be modified by treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)...
  12. doi request reprint A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis
    Ingar Holme
    Department of Endocrinology, obesity and preventive medicine, Oslo University Hospital, Ulleval, Oslo, Norway
    Heart 98:377-83. 2012
    ..Prognostic information for asymptomatic patients with aortic stenosis (AS) from prospective studies is scarce and there is no risk score available to assess mortality...
  13. doi request reprint Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic
    Silvia Rollefstad
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
    Ann Rheum Dis 72:1968-74. 2013
    ..To perform cardiovascular risk stratification in patients with inflammatory joint diseases (IJD) and treat to lipid targets according to recommendations...
  14. doi request reprint Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease
    Anne Grete Semb
    Diakonhjemmet Hospital, Oslo, Norway
    Arthritis Rheum 64:2836-46. 2012
    ....
  15. ncbi request reprint Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study
    Anne B Rossebø
    Division of Cardiology, Aker University Hospital, Oslo, Norway
    Am J Cardiol 99:970-3. 2007
    ..4+/-0.7 mmol/L (126 mg/dl). The SEAS Study is the largest randomized trial to date in patients with AS and will allow determination of the prognostic value of aggressive lipid lowering in such patients...
  16. doi request reprint HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men
    Per Torger Skretteberg
    Department of Cardiology, Oslo University Hospital, Ullevaal, Norway
    Atherosclerosis 220:250-6. 2012
    ..Increased PF is associated with increased HDL and may partly explain the benefit of HDL. We tested the hypothesis that PF influences the prognostic impact of HDL for CHD and also for CHD-, CVD- and all-cause death...
  17. ncbi request reprint Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy
    Anne G Semb
    Cardiologic Department, Aker Hospital, Oslo, Norway
    J Am Coll Cardiol 41:275-9. 2003
    ..In the present study, we investigated the effects of statins on serum levels of soluble CD40 ligand (sCD40L) in patients with familial hypercholesterolemia (FH)...
  18. ncbi request reprint Simvastatin: a review
    Terje R Pedersen
    Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    Expert Opin Pharmacother 5:2583-96. 2004
    ..Because of its long record of safety and demonstrated ability to reduce cardiovascular risk, simvastatin has recently become available without a prescription in the UK at the 10 mg dosage level...
  19. doi request reprint Left ventricular systolic and diastolic function in asymptomatic patients with moderate aortic stenosis
    Kjetil Steine
    Aker University Hospital, Oslo, Norway
    Am J Cardiol 102:897-901. 2008
    ..Augmented LV filling pressure measured by E/E'sep and impaired LV relaxation measured by reduced E'sep also indicate diastolic dysfunction in these patients...
  20. ncbi request reprint Hyperlipidaemia and aortic valve disease
    Anne Bjørhovde Rossebø
    Cardiology Department, Aker University Hospital, Oslo, Norway
    Curr Opin Lipidol 15:447-51. 2004
    ..This review addresses the role of the various risk factors and the potential for intervention...
  21. ncbi request reprint Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial
    James A de Lemos
    Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas Southwestern Medical Center, Dallas 75390 9047, USA
    JAMA 292:1307-16. 2004
    ..Limited data are available evaluating how the timing and intensity of statin therapy following an acute coronary syndrome (ACS) event affect clinical outcome...
  22. ncbi request reprint Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency
    Michel Chonchol
    Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Am J Kidney Dis 49:373-82. 2007
    ..Few studies examined the effects of statins on all-cause mortality and major coronary events in patients with renal dysfunction...
  23. doi request reprint Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
    Anne B Rossebø
    Division of Cardiology, Aker University Hospital, Trondheimsveien 235, N 0514 Oslo, Norway
    N Engl J Med 359:1343-56. 2008
    ..Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results...
  24. doi request reprint Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
    John J P Kastelein
    Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands
    Circulation 117:3002-9. 2008
    ....
  25. doi request reprint High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies
    Wim A van der Steeg
    Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
    J Am Coll Cardiol 51:634-42. 2008
    ....
  26. ncbi request reprint Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)
    Kalevi Pyorala
    Department of Medicine, Kuopio University Hospital, Kuopio, Finland
    Diabetes Care 27:1735-40. 2004
    ....
  27. ncbi request reprint Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
    Hallvard Holdaas
    Lancet 361:2024-31. 2003
    ..We investigated the effects of fluvastatin on cardiac and renal endpoints in this population...
  28. ncbi request reprint The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
    Cynthia J Girman
    Departments of Epidemiology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Am J Cardiol 93:136-41. 2004
    ..It appears that the metabolic syndrome is associated with risk that is not entirely accounted for by traditional risk scoring paradigms...
  29. ncbi request reprint fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study
    Alan G Jardine
    Western Infirmary, Glasgow, Scotland, UK
    Am J Transplant 4:988-95. 2004
    ..The subgroups included patients at lower cardiovascular risk, who were younger, nondiabetic, nonsmokers and without pre-existing CVD. These data support the early introduction of statins following renal transplantation...
  30. ncbi request reprint Prevention of cardiovascular ischemic events: high-risk and secondary prevention
    Jacques Genest
    Division of Cardiology, McGill University Health Center, Montreal, QC, Canada H3A 1A1
    Circulation 107:2059-65. 2003
  31. ncbi request reprint Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)
    Timo E Strandberg
    Department of Medicine, University of Helsinki, Helsinki, PL 340, 00029 HUS, Finland
    Lancet 364:771-7. 2004
    ..We extended post-trial follow-up of participants in the Scandinavian Simvastatin Survival Study (4S) to investigate cause-specific mortality and incidence of cancer 5 years after closure of the trial...
  32. ncbi request reprint Viewpoint: Terje R. Pedersen, MD, PhD. Interview by Robert Short
    Terje R Pedersen
    Circulation 115:f51-2. 2007
  33. ncbi request reprint Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998
    Terje R Pedersen
    Atheroscler Suppl 5:99-106. 2004
  34. ncbi request reprint Statin therapy: changing the mode of coronary heart disease
    Terje R Pedersen
    Cardiology 109:154-5. 2008
  35. ncbi request reprint Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management
    Alberico L Catapano
    Centre for the Study of Atherosclerosis, Marie Curie Training Centre for Cardiovascular Diseases, University of Milan, Milan, Italy
    Eur J Cardiovasc Prev Rehabil 14:340-5. 2007
    ..According to a recent report by the Stockholm Network (an independent European 'think tank'), major political, economic, social, and medical changes are urgently needed with respect to cholesterol management to help prevent CVD...